Chime Biologics, a global biologics contract development and manufacturing organisation (CDMO), has announced the inauguration of its GMP-2 manufacturing facility in Wuhan, China, further expanding its capacity to support growing global demand for biologics.
The new facility is equipped with eight 2,000-liter single-use Xcellerex bioreactors from Cytiva, a Danaher company and a leader in the life sciences industry, providing flexible and efficient capacity to support scale-up from discovery to delivery, while maintaining consistent quality.
This latest expansion builds on a decade of collaboration between Cytiva and Chime Biologics. The company’s first manufacturing facility was built using the KUBio modular manufacturing platform. The platform supported Chime Biologics’ growth from early-stage development to global commercial manufacturing, enabling a phased and efficient scale-up approach which aligned to customer needs.
Chime Biologics also announced plans on investing in a new AI-Powered Megafactory with over 100 2,000L bioreactors, which is expected to become the single largest biologics manufacturing campus in China.
The expansion further reinforces Chime Biologics’ position as a globally-oriented CDMO, with overseas markets already accounting for approximately 50% of total order value. Following the commissioning of the new GMP-2 facility, the company expects to increase the share of revenue from markets outside China to around 70% over the next five years.
